Bill would limit gifts, allow sampling
Bill would limit gifts,allow sampling
Representative Pete Stark (D-CA) has introduced the "Save Money for Prescription Drug Research Act of 2000," a bill that would deny tax deductions for certain gifts provided to physicians by drug manufacturers. If passed, the bill would not apply to samples.
Stark accused the pharmaceutical industry of spending twice as much money on marketing and administration as it does on research and development and called gifts to doctors "bribes." "Rather than spending pharmaceutical dollars on these very questionable gifts, the industry should devote the billions of dollars on life-saving drugs," Stark said in an introductory speech.
The bill would apply to all gifts "provided directly or indirectly to or for the benefit of a physician, including gifts of meals, sponsored teachings, symposia and travel."
"The need for this bill is clear," Stark said. "Denying the pharmaceutical industry the ability to deduct expenditures for gifts (other than product samples) to physicians is a critical step in providing Americans with access to more life-saving drugs. This will discourage drug company gifts that have been shown to sway physician prescribing behavior and free up more pharmaceutical revenue for R&D. By redirecting drug company promotional expenditures to their R&D budgets, the American public would reap the benefit of increased medical breakthroughs." PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.